Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of high-risk, locally advanced prostate cancer meeting ≥ 1 of the following criteria: * Clinical stage ≥ T3 * Gleason score ≥ 8 * PSA ≥ 20 ng/mL * Previously untreated disease * Non-metastatic disease as assessed by bone scan and CT scan of the thorax and abdomen * Negative pelvic lymph nodes as proven by pathological analysis PATIENT CHARACTERISTICS: * WHO performance status 0-1 * WBC ≥ 3.5 x 10\^9/L * ANC ≥ 1.5 x 10\^9/L * Platelets normal * Hemoglobin \> 10 g/dL * Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) * Albumin ≥ 3 g/dL * Serum transaminases activity ≤ 2.5 x ULN * Alkaline phosphatase ≤ 2.5 x ULN * Serum creatinine ≤ 1.5 x ULN * Covered by national health insurance * No history of previous malignant disease, except for adequately treated basal cell carcinoma of the skin * No ≥ grade 3 hypercholesterolemia/hypertriglyceridemia or ≥ grade 2 hypercholesterolemia/hypertriglyceridemia with history of coronary artery disease (despite lipid-lowering treatment, if given) * No uncontrolled infection * No dysphagia or intestinal malabsorption * No other concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes mellitus, uncontrolled cardiac disease \[unstable angina\], uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within the past six months, chronic liver or renal disease, and active upper gastrointestinal tract ulceration) * No history of noncompliance to medical regimens * No known hypersensitivity to everolimus, sirolimus (rapamycin), or temsirolimus * No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study treatment and follow-up schedule PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 30 days since prior investigational drugs * More than 10 days since prior and no concurrent treatment with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A